This disclosure relates to strategies for in vivo production of certain carbon-based products, for example, aminated aliphatic compounds having a carbon chain length of C5-C19.

The present invention relates to a sacubitril intermediate and a preparation method thereof. The sacubitril intermediate disclosed herein can be prepared by a deprotection reaction of a compound. In addition, the intermediate can be used as a raw material to synthesize sacubitril.

The present invention relates to a microorganism variant having the ability to extracellularly produce heme, and more particularly to a metabolically engineered microorganism variant having the ability to extracellularly produce heme and a method of producing heme using the same. According to the present invention, heme, an organometallic compound which is increasingly used as a health food or food supplement for the treatment of porphyria, can be extracellularly secreted and produced in high yield using the microorganism variant, but not conventional chemical synthesis or enzymatic synthesis.

Described herein are engineered cells including ones having synthetic methylotrophy which include an NADH-dependent enzyme capable of converting G3P to 3PG (e.g., B. methanolicus gapN) and/or fructose-1,6-bisphosphatase, along with hexulose-6-phosphate synthase, 6-phospho-3-hexuloisomerase, a phosphoketolase, or a combination thereof. Engineered cells of the disclosure beneficially maintain adequate pool sizes of phosphorylated C3 and/or C4 compounds, and/or provide increased levels of NADPH. As such, the modifications allow for the generation of C6 compounds from C1 (e.g., a methanol feedstod) and C5 compounds, the regeneration of C5 compounds from C6 compounds by carbon rearrangement, and an improved balance between regeneration of C5 compounds and lower glycolysis. In turn, this allows the engineered microorganism to generate sufficient quantities of metabolic precursors (e.g., acetyl-CoA) which can be used in a bioproduct pathway, and the engineered cells can include further modifications to those pathway enzymes allowing for production of a desired bioproduct.

Provided is a novel method for producing 4-aminocinnamic acid from 4-nitrophenylalanine. This method comprises: converting 4-nitrophenylalanine into 4-nitrocinnamic acid; and converting 4-nitrocinnamic acid into 4-aminocinnamic acid.

Described herein is a method for preparing an amino salt compound, the method including: i) providing a carbonyl compound; ii) reacting the carbonyl compound provided according to (i) in the presence of a transaminase with ii-a) at least one primary amine; and ii-b) at least one carboxylic acid; thereby obtaining a mixture including an at least partially crystallized amino salt compound including a cation and a carboxylate anion based on the at least one carboxylic acid added according to (ii-b). Also described herein is an amino salt compound obtained or obtainable by the method and to the amino salt compound, and a composition including a) an amine of general formula (IIa); and b) at least one carboxylic acid of general formula (III).

The present invention provides amino acid sequences of engineered decarboxylase polypeptides that are useful for catalyzing the decarboxylation of L-aspartate to produce β-alanine, and the preparation process of engineered decarboxylase polypeptides as well as reaction process under industrial-relevant conditions. The present disclosure also provides polynucleotide sequences encoding engineered decarboxylase polypeptides, engineered host cells capable of expressing engineered decarboxylase polypeptides, and methods of producing β-alanine using the engineered cells. Compared to the wild-type decarboxylase, the engineered decarboxylase polypeptide provided by the invention has better activity and stability, and overcomes the inhibition by L-aspartic acid and/or β-alanine. The use of the engineered polypeptides of the present invention for the preparation of β-alanine results in higher unit activity, lower cost, and has good industrial application prospects.

Provided is a method for manufacturing a 3-hydroxy-4-aminobenzoic acid by using a microorganism. The method for manufacturing a 3-hydroxy-4-aminobenzoic acid comprises a step of bringing a 4-aminobenzoic acid into contact with a microorganism that produces the following polypeptide (A) or (B): (A) a polypeptide consisting of an amino acid sequence shown in SEQ ID NO: 2 or a polypeptide consisting of an amino acid sequence that has at least 90% identity to the amino acid sequence shown in SEQ ID NO: 2 and has 4-hydroxybenzoate hydroxylase activity, (B) a polypeptide consisting of an amino acid sequence shown in SEQ ID NO: 6 or a polypeptide consisting of an amino acid sequence that has at least 90% identity to the amino acid sequence shown in SEQ ID NO: 6 and has 4-hydroxybenzoate hydroxylase activity.

The present disclosure relates to compositions and methods for producing stereoisomerically pure aminocyclopropanes.

A method for the use of a cytochrome P450 enzyme comprising any of SEQ ID NO: 1-118, or mutants thereof or a variant enzyme having at least 70% identity thereto and having CYP450 activity, for the hydroxylation and or dealkylation of an organic compound.

##STR00001## ##STR00002## ##STR00003## ##STR00004##